CoRISMA develops a catheter-delivered, fully implanted mechanical circulatory assist device that provides continuous blood flow for patients with advanced heart failure. This system addresses the limitations of existing heart failure treatments by offering a minimally invasive solution that reduces the economic burden of managing this condition.
Funding
$27.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with advanced heart failure often face limitations with existing treatments, which can be expensive, highly invasive, and require long hospitalizations and close clinical monitoring. Current options may not be accessible in many countries despite the high global prevalence and economic burden of the condition.
Solution
CoRISMA develops a catheter-delivered, fully implanted mechanical circulatory assist device designed to provide continuous blood flow for patients with advanced heart failure. The CoRISMA Heart Failure System is a transcatheter device that is wirelessly powered, offering a less invasive and potentially more cost-effective alternative to existing heart failure treatments. The device aims to reduce the economic burden associated with managing advanced heart failure while expanding the market for heart failure devices.
Target Audience
The primary target audience includes patients suffering from advanced heart failure and clinicians seeking alternatives to existing treatments.
Features
- Catheter-delivered implantation for minimally invasive placement
- Fully implanted system for long-term circulatory support
- Wireless power transmission for device operation
- Mechanical circulatory support to augment heart function